Hepatitis C and renal transplantation in era of new antiviral agents

doi:10.5500/wjt.v8.i4.84

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7217)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

425

WORD

225

HTML

3125

Figures (1-3)

174

Tables (1-6)

179

Sum=4128

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

491

Download

813

Sum=1304

Publishing Process of This Article

Item

Count

Browse

836

Download

949

Sum=1785

Aug 9, 2018 (publication date) through May 13, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Aug 9, 2018; 8(4): 84-96
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.84

Table 2 Available, approved direct acting antiviral-based regimens for treating hepatitis C virus in treatment-naive patients

Genotype 1a	Genotype 4
Ledipasvir + sofosbuvir Paritaprevir + ritonavir + ombitasvir + dasabuvir Sofosbuvir+ simeprevir ± ribavirin	Ledipasvir + sofosbuvir Paritaprevir + ritonavir + ombitasvir + dasabuvir + ribavirin Sofosbuvir + ribavirin + pegIFN Sofosbuvir + simeprevir + ribavirin
Genotype 1b	Genotype 5
Ledipasvir + sofosbuvir Paritaprevir + ritonavir + ombitasvir + dasabuvir Sofosbuvir + simeprevir	Sofosbuvir + ribavirin PegIFN + ribavirin
Genotype 2	Genotype 6
Sofosbuvir + ribavirin	Ledipasvir + sofosbuvir Sofosbuvir + ribavirin + pegIFN
Genotype 3	Pangenotype
Sofosbuvir + ribavirin Sofosbuvir + ribavirin + pegIFN	Glecaprevir + pibrentasvir Sofosbuvir + velatapasvir

pegIFN: Pegylated interferon.

Citation: Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96
URL: https://www.wjgnet.com/2220-3230/full/v8/i4/84.htm
DOI: https://dx.doi.org/10.5500/wjt.v8.i4.84